La Rocca, E.
De Santis, M. C.
Silvestri, M.
Ortolan, E.
Valenti, M.
Folli, S.
de Braud, F. G.
Bianchi, G. V.
Scaperrotta, G. P.
Apolone, G.
Daidone, M. G.
Cappelletti, V.
Pruneri, G.
Di Cosimo, S. http://orcid.org/0000-0002-4666-8052
Article History
Received: 8 March 2022
Accepted: 20 March 2022
First Online: 9 April 2022
Declarations
:
: ELR, MCD, MS, EO, MV, SF, GVB, GS, GA, MGD, and VC: none; FGdB: speakers bureau honoraria from BMS, Eli Lilly, Roche, Amgen, AstraZeneca, Gentili, Fondazione Menarini, Novartis, MSD, Ignyta, Bayer, Noema SRL, ACCMED, DEPHAFORUM SRL, Nadirex, Roche, Biotechspert Ltd., PriME Oncology, Pfizer, consultant/advisory board fees from BMS, Tiziana Life Sciences, Celgene, Novartis, Servier, Phanm Research Associated, Daiichi Sankyo, Ignyta, Amgen, Pfizer, Roche, Teogarms, and Pierre Fabre; GP: honoraria from Roche, GSK, Genomic Health, and Hybrid Genetic; SDC: consulting fees from Pierre-Fabre, IQVIA.
: This study was performed in line with the principles of the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.